QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 510 participants.

Also called NCT07444086

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 510 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07444086
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07444086. Randomized; quadruple masking; primary purpose treatment. Start 2026-03-05 (anticipated); primary completion 2027-10-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia
Condition
Primary Hypercholesterolemia or Mixed Hyperlipidemia
Intervention (Drug)
QLC7401
Intervention (Drug)
Placebo
Lead sponsor
Qilu Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07444086
Content hash
32e9e5ddf73c820a5b3734f2ac098441381de11fc2287e5e4b99f54e27eb8397